• Adverse event rates occurring in the pilot study population will be compared between the cord blood cell recipients and historical controls from the Network Hypothermia study. [ Time Frame: during infusions: first 4 postnatal days ] [ Designated as safety issue: Yes ]
  

• Secondary endpoints of this pilot study will include preliminary efficacy as measured by neurodevelopmental function at 4 - 6 months and 9 - 12 months of age [ Time Frame: 1 year ] [ Designated as safety issue: No ]
  
• neuroimaging results will be collected and compared with available results from prior trials of therapies in this population, and from a previously collected set of images from normal term newborns through the first year of life. [ Time Frame: 6 months ] [ Designated as safety issue: No ]
  

The purpose of this pilot study is to evaluate the safety and feasibility of infusions of autologous (the patient's own)umbilical cord blood cells in term gestation newborn infants with hypoxic-ischemic encephalopathy. For this study, infants whose mothers have previously consented to providing cord blood cells for the Carolinas Cord Blood Bank or provided verbal consent for cord blood collection for the possibility of their baby's participation in this trial, who have adequate cord blood collected, and have signs of moderate to severe encephalopathy will be given cells in addition to current therapies used at the study institution, Duke. Study activities also include serial blood draws concurrent with clinically indicated blood draws with a total volume of no more than 5 milliliters (1 teaspoon) from all study related tests. Babies will be followed for neurodevelopmental outcome at 4 - 6 and 9 - 12 months at Duke's Special Infant Care Clinic. MRI's will be obtained between postnatal weeks 1 and 4, and, for study purposes at 4 - 6 postnatal months.